At day 17 post-tumor challenge, QBKPN administration resulted in an overall increase in CD45+ cells (data not shown) in the lungs and a noticeably different immune cell profile compared to placebo (Fig. 4D). This evidence concerns the gene PTPRC and neoplasm.